Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Aldeyra Therapeutics, Inc.ALDX · Entity 6839 | Chief Commercial Officer | March 02, 2020 | March 06, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Aldeyra Therapeutics, Inc.
Report date March 02, 2020 · Filed March 06, 2020 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 255,183 |
Reported balance
After 2020-03-02 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2020-03-02 · Grant · Acquired 247,480 · Balance 255,183 F1: Represents shares of common stock underlying a time-based restricted stock unit award (RSU). The RSU vests ratably in equal annual installments over a four-year period beginning on January 1, 2020, provided that the Reporting Person has provided continuous service to the Issuer through the applicable vesting date. F2: Includes an additional 1,555 shares of common stock previously acquired under the Issuer's Employee Stock Purchase Plan. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.78 · Expires 2030-03-01 | Direct | 250,000 |
Reported balance
After 2020-03-02 transaction · row 2
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 2 · 2020-03-02 · Grant · Acquired 250,000 · Balance 250,000 F3: The shares subject to this option shall vest in equal monthly installments over the next 48 months of continuous service to the Issuer after January 1, 2020. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of common stock underlying a time-based restricted stock unit award (RSU). The RSU vests ratably in equal annual installments over a four-year period beginning on January 1, 2020, provided that the Reporting Person has provided continuous service to the Issuer through the applicable vesting date.
F2: Includes an additional 1,555 shares of common stock previously acquired under the Issuer's Employee Stock Purchase Plan.
F3: The shares subject to this option shall vest in equal monthly installments over the next 48 months of continuous service to the Issuer after January 1, 2020.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 02, 2020 Filed Mar 5, 2020 00:46 UTC | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | GrantEmployee Stock Option (Right to Buy) · Derivative | 247,480 | $0.00 Strike: $3.78 | $0.00 |
DisclosureSEC source: 0000899243-20-007064 · doc4.xml · derivative · entry 2 McMullin David · CIK 0001738662 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 247,480 Underlying: Common Stock · 247,480 shares Expires 2030-03-01 F3 · derivative.exercise_date: The shares subject to this option shall vest in equal monthly installments over the next 48 months of continuous service to the Issuer after January 1, 2020. Read SEC document |
| March 02, 2020 Filed Mar 5, 2020 00:46 UTC | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | GrantCommon Stock | 250,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-007064 · doc4.xml · nonDerivative · entry 1 McMullin David · CIK 0001738662 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 257,703 F1 · shares: Represents shares of common stock underlying a time-based restricted stock unit award (RSU). The RSU vests ratably in equal annual installments over a four-year period beginning on January 1, 2020, provided that the Reporting Person has provided continuous service to the Issuer through the applicable vesting date. F2 · balance_after: Includes an additional 1,555 shares of common stock previously acquired under the Issuer's Employee Stock Purchase Plan. Read SEC document |
| March 02, 2020 Filed Mar 6, 2020 21:42 UTC Amendment | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | GrantEmployee Stock Option (Right to Buy) · Derivative | 250,000 | $0.00 Strike: $3.78 | $0.00 |
DisclosureSEC source: 0000899243-20-007447 · doc4a.xml · derivative · entry 2 McMullin David · CIK 0001738662 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2030-03-01 F3 · derivative.exercise_date: The shares subject to this option shall vest in equal monthly installments over the next 48 months of continuous service to the Issuer after January 1, 2020. Read SEC document |
| March 02, 2020 Filed Mar 6, 2020 21:42 UTC Amendment | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | GrantCommon Stock | 247,480 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-007447 · doc4a.xml · nonDerivative · entry 1 McMullin David · CIK 0001738662 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 255,183 F1 · shares: Represents shares of common stock underlying a time-based restricted stock unit award (RSU). The RSU vests ratably in equal annual installments over a four-year period beginning on January 1, 2020, provided that the Reporting Person has provided continuous service to the Issuer through the applicable vesting date. F2 · balance_after: Includes an additional 1,555 shares of common stock previously acquired under the Issuer's Employee Stock Purchase Plan. Read SEC document |
| September 05, 2019 Filed Sep 9, 2019 20:37 UTC | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | PurchaseCommon Stock | 4,329 | $4.68 | $20,259.72 |
DisclosureSEC source: 0000899243-19-023128 · doc4.xml · nonDerivative · entry 1 McMullin David · CIK 0001738662 · Chief Commerical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,148 F1 · balance_after: Includes 1,819 shares of common stock acquired under the Issuer's Employee Stock Purchase Plan (ESPP) in 2019. Read SEC document |
| March 05, 2019 Filed Mar 7, 2019 22:30 UTC | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | GrantEmployee Stock Option (Right to Buy) · Derivative | 45,212 | $0.00 Strike: $8.05 | $0.00 |
DisclosureSEC source: 0000899243-19-006734 · doc4.xml · derivative · entry 1 McMullin David · CIK 0001738662 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,212 Underlying: Common Stock · 45,212 shares Expires 2029-03-04 F1 · derivative.exercise_date: The shares subject to this option shall vest in equal monthly installments over the next 48 months of continuous service to the Issuer after January 1, 2019. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.